> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Ozempic Kidney Study Stopped Due to Efficacy Data
- URL: https://www.fdaweb.com/ozempic-kidney-study-stopped-due-to-efficacy-data/
- Published: 2023-10-11T12:00:00.000Z
- Updated: 2026-09-14T19:01:50.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5155537

Positive efficacy data have prompted Novo Nordisk to stop a kidney outcomes trial (FLOW) that was studying the effects of Ozempic (semaglutide) versus placebo on the progression of renal impairment in people with Type 2 diabetes and chronic kidney disease (CKD). The company says its decision to stop FLOW was based on a recommendation from an independent data monitoring committee that concluded the results from an interim analysis met certain pre-specified efficacy criteria for stopping the trial early. It expects a data readout during the first half year of 2024.

FLOW involved 3,534 enrolled patients in 28 countries at more than 400 investigator sites. “The key objective of the FLOW trial was to demonstrate delay in progression of CKD and to lower the risk of kidney and cardiovascular mortality,” the company says.

Ozempic is indicated as an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus and to reduce the risk of major adverse cardiovascular events in adults with Type 2 diabetes mellitus and established cardiovascular disease.